Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 20/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 19/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 19/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18695483 | 0.99 | PIM1 (0.51) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL17136318 | 0.88 | PIM1 (0.59) | PIM1PIM3PIM2 | |
| SCHEMBL17136278 | 0.86 | PIM3 (0.53) | PIM1PIM3PIM2 | |
| SCHEMBL17136302 | 0.86 | PIM1 (0.54) | PIM1PIM3PIM2GSK3BPRKCQ | |
| Hydrochloric Acid SCHEMBL18695513 | 0.85 | PIM3 (0.53) | PIM1PIM3PIM2 | |
| Hydrochloric Acid SCHEMBL18695506 | 0.85 | PIM1 (0.53) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL17140199 | 0.85 | PIM1 (0.46) | PIM1PIM3PIM2GSK3BPRKCQ | |
| Hydrochloric Acid SCHEMBL18696137 | 0.84 | PIM1 (0.45) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL17136285 | 0.83 | PIM1 (0.72) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL17136277 | 0.82 | PIM1 (0.72) | PIM1PIM3PIM2GSK3BPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | claimed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | claimed |
| US-10174002-B2 | Pyridine derivatives as CFTR modulators | NuBridge BioSciences (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170101394-A1 | PYRIDINE DERIVATIVES AS CFTR MODULATORS | NuBridge BioSciences | 2017-04-13 | — | — | US | disclosed |
| US-20170101394-A1 | PYRIDINE DERIVATIVES AS CFTR MODULATORS | NuBridge BioSciences | 2017-04-13 | — | — | US | disclosed |
| WO-2017045615-A1 | PYRIDINE DERIVATIVE PIM KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE PREPARATION | 上海吉铠医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174002-B2 | Pyridine derivatives as CFTR modulators | CFTR, SCNN1B, SLC26A4 | PIM1 3664/4885PIM3 4136/4885PIM2 3332/4885 |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20170101394-A1 | PYRIDINE DERIVATIVES AS CFTR MODULATORS | CFTR, SCNN1B, SLC26A4 | PIM1 3489/4885PIM3 4030/4885PIM2 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.